论文部分内容阅读
[目的]探讨延边地区TP53基因-72密码子多态性位点(TP53-rs1042522C>G)与宫颈癌预后的相关性.[方法]选择在延边大学附属医院和延边肿瘤医院接受治疗的宫颈癌患者403例(Ⅰ期21例、Ⅱ期245例、Ⅲ期132例、Ⅳ期3例、分期不详2例),给予抗癌治疗前采集外周静脉血,提取基因组DNA,利用聚合酶链反应-限制性片段长度多态性方法对TP53-rs1042522C>G进行分型.[结果]CC,CG和GG基因型在宫颈癌中的频率分别为23.3%,54.4%和22.3%,CC基因型总生存率显著低于GG,CG和CC+CG基因型(P=0.001,P=0.000 1).无病生存率分析结果显示,CC基因型总生存率显著低于GG,CG和CC+CG基因型(P=0.017,P=0.003),提示CC变异型宫颈癌患者总生存率和无病生存率显著低于其他基因型.[结论]TP53-rs1042522C>G可作为宫颈癌治疗后预测总生存率和无病生存率的生物标志物.
[Objective] To explore the correlation between TP53 gene -72 codon polymorphism (TP53-rs1042522C> G) and the prognosis of cervical cancer in Yanbian area. [Methods] Cervical cancer treated in Yanbian University Hospital and Yanbian Cancer Hospital Patients: 403 patients (21 cases of stage Ⅰ, 245 cases of stage Ⅱ, 132 cases of stage Ⅲ, 3 cases of stage Ⅳ, 2 cases of unknown stage). Peripheral venous blood was collected before anticancer treatment. Genomic DNA was extracted and analyzed by polymerase chain reaction- The frequencies of CC, CG and GG genotypes in cervical cancer were 23.3%, 54.4% and 22.3%, respectively. The overall genotype frequency of CC genotype The overall prevalence of CC genotype was significantly lower than that of GG, CG and CC + CG genotypes (P = 0.001, P = 0.000 1) (P = 0.017, P = 0.003), suggesting that the overall survival and disease-free survival of patients with CC variant cervical cancer were significantly lower than other genotypes. [Conclusion] TP53-rs1042522C> G can be used as a prediction of overall survival after cervical cancer treatment And disease-free survival biomarkers.